Bio-Rad Introduces New Bio-Plex® Assays for Immunology and Cancer Biomarker Research

Human Th17
The Bio-Plex Pro Human Th17 Cytokine Panel and Bio-Plex Pro Human Cancer Biomarker Panel 1 deliver high-performance multiplex assays for immunology and cancer research, respectively.

Hercules, CA — March 6, 2012 — Bio-Rad Laboratories announced the launch of its new magnetic bead–based multiplex immunoassays for human T-helper type 17 (Th17) cytokines and cancer biomarkers. The Bio-Plex Pro™ immunoassays take advantage of the magnetic bead workflow to simplify assay preparation and reduce variability.

The Bio-Plex Pro Human Th17 cytokine panel detects 16 soluble proteins involved in the Th17 immune response pathway. The Bio-Plex Pro human cancer biomarker panel 1 detects 16 biomarkers commonly associated with cancer. These assays are designed to help preclinical and clinical researchers investigate mechanisms of disease and therapeutic drug action.

The Bio-Plex Pro Human Th17 cytokine panel features nine new targets, including IL-17F, IL-21, and IL-22, which are commonly requested by researchers, as well as IL-17 A/F, which is unique to Bio-Rad. The Th17 cytokines are believed to play a key role in inflammatory conditions such as autoimmune diseases, antimicrobial immunity, transplant rejection, and cancer.

The Bio-Plex Pro human cancer biomarker panel 1 incorporates eight new targets including sEGFR, sVEGFR-1, and osteopontin, as well as three targets unique to the Bio-Plex system: sTIE-2, follistatin, and PECAM-1. These targets are associated with the progression of cancer, including sustained angiogenesis, self-sufficiency in growth signals, and tissue invasion and metastasis.

Bio-Plex Pro assays provide many advantages over other xMAP and ELISA offerings, including:

  • Faster assay run time — shorter (one hour) incubation times yield results in three hours compared to other assays, which require overnight incubation
  • Better performance — broader assay working range for increased confidence in sample detection, higher precision, and higher sensitivity (0.1 pg/ml for some assays)
  • Flexible ordering options — choice of fixed panels, singleplex sets, or custom panels (premium “we mix” and economical “you mix” options) designed with the online Bio-Plex Assay Builder

The Bio-Plex Pro human Th17 cytokine and human cancer biomarker assays are compatible with all Bio-Plex readers, as well as Luminex 200, FLEXMAP 3D, and MAGPIX instruments.

For more information on Bio-Rad’s Bio-Plex product portfolio, please visit

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies, for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The Company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Brett Houser
Bio-Rad Laboratories, Inc.

Ken Li
Chempetitive Group
312-997-2436 x 109